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1. Introduction 
Paediatric respiratory tract infections are one of the most common reasons for physician 
visits and hospitalisation, and are associated with significant morbidity and mortality. 
Respiratory infections are common and frequent diseases and present one of the major 
complaints in children and adolescents. The role of physicians and other healthcare 
providers has expanded from merely treating disease to implementing measures aimed at 
health maintenance and disease prevention (Bellanti, 1997). Respiratory infections (RI), 
mainly involving the upper airways, are common in children and their recurrence 
constitutes a demanding challenge for the paediatricians. There are many children suffering 
from so-called recurrent respiratory infections (RRI). The child with recurrent respiratory 
infections presents a difficult diagnostic challenge. It is necessary to discriminate between 
those with simply-managed cause for their symptoms such as recurrent viral infections or 
asthma, from the children with more serious underlying pathology such as bronchiectasis or 
immune dysfunction. Many different disorders present this way, including cystic fibrosis, 
various immunodeficiency syndromes, congenital anomalies of respiratory tract, but in 
some children lung damage could follow a single severe pneumonia or can be the 
consequence of the inhalation of food or foreign body (Couriel, 2002). According to the 
epidemiological studies it was estimated that around 6% of the children younger than 6 
years of age present RRI. In developed countries, up to 25% of children aged < 1 year and 
18% of children aged 1-4 years experience RRI (Bellanti, 1997). Moreover, ENT infections 
represent the most frequent pathologies in children aged from 6 months to 6 years. 
Although the etiologic agents responsible for RRI are not always readily identifiable, viral 
agents are typically the main cause. The real task for the paediatricians is to discriminate the 
normal children with high respiratory infections frequency related to an augmented 
exposure to environmental risk factors from the children affected by other underlying 
pathological conditions (immunological or not), predisposing to infectious respiratory 
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diseases (de Martino & Ballotti, 1981). Usually, the children with RRI are not affected by 
severe alterations and RRI represent essentially the consequence of an increased exposure to 
infectious agents due to environmental factors during the first years of life (Arden et al., 
2006).  
In the clinical practice, most of the children suffer from the recurrent infections of the upper 
airways, but in approximately 10-30%, the lower tract is also affected. There are two peaks 
of the incidence of RRI (Couriel, 2002): 
 6-12 months of age ń after consumption of the maternal passively transferred 
immunoglobulins with concomitant postponed synthesis of own antibodies, 
 the involvement of the child in to the group of children at nursery or school. 
Upper respiratory infections are common but are unlikely to indicate an underlying medical 
condition when they occur in isolation (Wood, 2009). When evaluating the patients with 
recurrent infections, it is reasonable to use acronym SPUR (severe, persistent, unusual, 
recurrent) to prompt appropriate investigations for underlying causes. Children with RRI have 
the course of the airway infections (feature, severity and duration) similar to those presented 
by children with “normal” incidence of respiratory infections. The frequency of RI in children 
with RRI shows typical seasonality with the highest rate during autumn and winter (Arden et 
al., 2006). Typically, these children are not affected by the recurrent infections of the other 
systems (gastrointestinal tract, central nervous system, uro-genital tract or skin). While most 
children with recurrent infection have a normal immunity, it is important to recognize the 
child with an underlying primary immunodeficiency and investigate and treat appropriately 
and not over-investigate normal children (Slatter & Gennery, 2008). 
RRI are a common problem mainly in preschool age, usually due to the presence of 
unfavourable environmental conditions, including early socialization, as well as the 
immaturity and inexperience of the immune system (Dellepiante et al., 2009). In infancy and 
early childhood the immune system encounters antigens for the first time, mounting 
immune responses and acquiring memory. Young children mix with other children in 
families or nursery and are exposed to many pathogens and therefore there are more 
vulnerable to infection and recurrent infections are common (Slatter & Gennery, 2008). 
Many of the children are simply having the repeated viral upper respiratory tract infections 
that are a normal part of growing up. In others, the symptoms are the first manifestations of 
asthma. If there is a history of persistent or recurrent pneumonia with or without chronic 
sputum production, it is indicating more severe pathology (Couriel, 2002). RRI initially 
occur as a viral respiratory tract infection, but bacterial growth is demonstrated in 60% of 
patients with symptoms of an upper respiratory tract infection of at least 10 days duration 
(Kowalska et al., 2003; Salami et al., 2008). The children with prolonged or recurrent 
respiratory illnesses most often have a series of infections rather than persistent infection 
with one virus strain (Jartti et al., 2008). Some children experience considerable morbidity as 
a result of RRI and receive repeated courses of antibacterials that are not effective against 
viral infectious agents and can increase bacterial resistance (Bousquet & Fiocchi, 2006). 
2. Recurrent respiratory infections – definition 
Definition of RRI is problematic and clear consensus does not exist. In case of otitis media, a 
reference standard for occurrence is three episodes within 6 months or four episodes within 
12 months. Recurrent infectious rhinitis is usually defined as more than five episodes per 
year and recurrent pharyngitis or tonsillitis more than three episodes within 12 months 
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(Bellanti, 1997; Graham, 1990; Teele et al., 1989). Every definition of RRI is arbitrary and too 
generic and restrictive. Rather then defining if a child has recurrent infections with an 
objective numeric evaluation, it is better to know (Don et al., 2007): 
 if the child generally feels good, 
 if there are conditions that could be diagnosed and treated as a true disease,  
 if the findings on the history and physical examination are suggestive of an 
immunodeficiency. 
It is evident, that only a few appropriate tests are enough helpful to discriminate between a 
“well-being” child and a patient with immune dysfunction (Woroniecka & Ballow, 2000). 
It has been proposed that to diagnose RRI at least one of the following criteria has to be 
present (Gruppo di Studio di Immunologia della Societá Italiana di Pediatria, 1988): 
  ≥ 6 respiratory infections per annum, 
 ≥ 1 respiratory infections per month involving the upper airways from September to 
April, 
 ≥ 3 respiratory infections per annum involving the lower airways. 
3. “Physiological” respiratory morbidity 
Most children with RRI do not have any serious underlying immunological or non-
immunological pathology, it is possible to talk about “physiologic” respiratory in children. It 
means that certain number of respiratory infections can be considered as physiological due to 
the development of immature immune system in these children. The normal frequency of the 
respiratory tract is six to eight episodes during the autumn and winter in infancy (in children 
aged 1-5 years) and two to four episodes in older children (aged 6-12 years). Even the higher 
frequency of respiratory infections can be a source of great worry of the parents or 
paediatricians, most of the children with RRI are practically not ill and we are not able to 
detect any serious underlying illness or disturbance of immune system (de Vries, 2001).  
4. Immunology of recurrent respiratory infections 
The recurrent respiratory infections in infants and children are among the most common 
causes of counselling and admission to the hospital. They are responsible for significant 
morbidity measured by school days lost. Many factors can play an important role in the 
genesis of the episodes of RRI that can act alone or together. In some children, it is possible 
to detect also transient or permanent immune system deficiencies (Bellanti, 1997). It should 
be pointed, that a true immunodeficiency is rare and the first cause of RRI is the childhood 
itself (Wheeler, 1996), because both humoral and phagocytic immunity reach their best 
efficacy during the first fifth or sixth years of age (Wheeler & Steiner, 1992; Yang & Hill, 
1991). Typically, children with RRI are usually not affected by severe alterations of the 
immune system functions. The majority of these children do not have recognised 
immunodeficiencies, but some may have low levels of some laboratory parameters, usually 
of immunoglobulin isotypes or rarely other immunological parameters such as 
phagocytosis. Some of the observed immunological alterations are of questionable 
significance and not convincingly related to an increased susceptibility to respiratory 
infections (Litzman et al., 1999). Most children with RRI do not have an immunodeficiency. 
If they do, this is often due to an antibody deficiency. Finocchi et al. (2002) evaluated 
humoral immune defects in apparently 67 non-atopic patients with recurrent infections and 
in 55% a humoral defect was diagnosed.  
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According to the literature, several alterations in immune system and its function have been 
observed among children suffering from RRI (Atkinson et al., 2004; Bossuyt et al., 2007; Day 
et al., 2004; de Martino & Ballotti, 2007; Don et al., 2007; Finocchi et al., 2002; Gomi et al., 
2004; Ianni et al., 2001; Kvestad et al., 2006; Li Volti et al., 2003; Ottenhoff et al., 2002; Pryjma 
et al., 1999): 
 defects of FcǄ receptor IIIa (CD16) on natural killer cells, 
 defect of interleukin receptor-associate kinase 4 (IRAK4), 
 reduction in IL-12 production, 
 polymorphisms in genes CCR2, CCR5 and mannose-binding lectin gene, 
 mutations in TLR-4 encoding sequences, 
 defective removal of the apoptotic neutrophils by alveolar macrophages, 
 pathologic phagocytosis and production of reactive oxygen intermediates from 
polymorphonuclear cells, 
 decrease neutrophil chemotaxis, 
 mild decrease in the number of CD4+, CD8+, CD19+ and NK-cells, 
 alterations in the cytokine production by lymphocytes (Ń IL-4, Ń IL-10, Ņ IFN-Ǆ, Ņ IL-2), 
 decreases IgM, IgA, IgG subclasses, mannose-binding lectin, L-ficolin, 
 defects in the production post-infectious specific antibodies. 
The children with estimated diagnosis of RRI usually have no significant alteration of the 
immune system and its functions. Coexistence of two or more partial mild immune 
deteriorations in children with RRI, which was observed by several authors, confirms the 
secondary post-infective nature of these changes (Bossuyt et al., 2007). It is probable, that all 
the observed non-specific deteriorations of immunity are rather the consequence of repeated 
viral infections than the predisposing factor leading to RRI. Various infections (especially 
viral) can influence immune reaction, cytokine responses and phagocytosis. The 
combination of RRI and viral infection can lead to the deeper virus-induced immune 
dysfunction which can favour the recurrence of further respiratory infections (de Martino & 
Ballotti, 2007; Li Volti et al., 2003).  
5. Recurrent respiratory infections as a warning sign of primary 
immunodeficiencies 
Primary immunodeficiencies (PID) are generally the results of genetic defects that interfere 
with a component of the immune system. In general, these disorders are rare with some 
exceptions such as selective IgA deficiency or mannose-binding lectin deficiency. The most 
frequent PID are usually asymptomatic or have only mild clinical symptoms.  
An underlying immunodeficiency is more likely when some of the following “warning” 
symptoms or signs occur (Champi et al., 2002; Slatter & Gennery, 2008): 
 eight or more new ear infections (otitis media) within 12 months, 
 two or more serious sinus infections within 12 months, 
 two or more episodes of pneumonia within 12 months, 
 two or more invasive infections in the history (meningitis, cellulitis, osteomyelitis, 
septicaemia), 
 failure of an infant to gain weight or grow normally ± chronic diarrhoea, 
 recurrent deep skin or organ abscesses, 
 persistent superficial candidiasis after age 1 year, 
 two or more months on antibiotics with little or no effect, 
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 need for intravenous antibiotics to clear infections, 
 a family history of primary immunodeficiency. 
A pattern of recurrent or persistent infection is the major manifestation of primary 
immunodeficiencies. While most children with RRI have normal immunity, it is essential to 
recognise the child with underlying PID and investigate and treat appropriately. Prompt, 
accurate diagnosis of PID helps to direct the most appropriate treatment, predict prognosis 
and facilitate genetic counselling for the family.  
6. Risk factors for recurrent respiratory infections 
The increased prevalence of RRI in younger children could be attributed to the several 
factors (de Martino & Ballotti, 2007): 
 increased exposure to infectious agents during the first years of life, especially when the 
child is attending a group of children at preschool- or school facilities, 
 general immaturity of the immune system of younger children, 
 social and environmental factors e.g. day-care attendance, family size, air pollution, 
parental smoking, home dampness. 
To the risk factors contributing to the increased frequency of respiratory infections in 
children with RRI belong (Ballow, 2008; Bellanti, 1997; Bloomberg, 2011; Bousquet & Fiocchi, 
2007; de Martino & Ballotti, 2007, Don et al., 2007; Karmaus et al., 2008; Wheeler, 1996): 
 day-care attendance, 
 early socialization, 
 large family size, overcrowding, 
 positive family history on atopic diseases, 
 school-aged siblings,  
 praematurity, 
 low bodyweight infants, 
 reduction of breast-feeding, 
 climate and environmental factors (indoor and outdoor pollutions exposure), 
 home dampness, 
 pets at home (especially cats and dogs), 
 parental smoking and smoking in pregnancy, 
 anatomic or functional alterations of the upper or lower airways, 
 allergy/atopy, 
 gastroesophageal reflux, 
 male gender, 
 poor socio-economic conditions with malnutrition, 
 intense training and physical stress, 
 missed vaccination. 
6.1 Day-care attendance 
Comparing the children in day-care centres with those cared at home, the first one have 
substantially higher risk of acute respiratory infections. Approximately 70% of the children 
with RRI attend day-care centres and about 75% of them start to suffer from RRI during 
their first year at child-care facilities (Celedon et al., 1999). Early enrolment can although on 
one side accelerate the acquisition of immunological experiences, but on the other hand this 
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requires the cost on the disease because of the naivety of the immune system. The younger 
the child, the greater risk of developing of symptomatic infection and therefore the 
postponed enrolment of children at day-care centres may prevent this excess risk of acute 
respiratory illness (de Martino & Balloti, 2007; Kamper-Jorgensen et al., 2006). It is known, 
that children attending day care outside home are more likely to have infections than 
children in home care. Early recurrent infections in early life are associated with asthma and 
reduced lung functions (Shaheen et al., 1994), although it has also been suggested that such 
infections may have a protective effect on later asthma (Cookson & Moffatt, 1997). It was 
confirmed that also the number of the children in collective have influence on the incidence 
of RRI (Marbury et al., 1997).  
6.2 Indoor pollution and climate 
It was showed that dose-response relation between the number of cigarettes smoked in the 
home and RI in children exists (Jaakkola et al., 2006; Stick, 2006). Maternal smoking during 
the pregnancy can influence the development of the immune system of the infants (Noakes 
et al., 2006). Passive smoking, allergic inflammation and predisposing anatomic variants 
play an important role in RRI (Arrieta et al., 2004). The exposure to home dampness and 
moulds (especially early in life), increased the risk of the development of atopic diseases and 
common respiratory infections.  
6.3 Outdoor pollutions 
It has been observed the relation between the outdoor pollutions (e.g. SO2, NO2) and the 
augmented respiratory symptoms, reduced expiratory flow rates, incidence of chronic 
cough or the increased risk of hospitalization due to respiratory infections (Colley, 1975; 
Chauhan & Johnston, 2003).  
6.4 Physical stress 
The association between increased psychical and physical stress and the frequency of 
respiratory infections was suggested by several studies. Highly trained athletes present a 
higher risk of RRI incidence. During the extreme physical stress several deterioration in the 
immune system have been reported (e.g. transitory decrease in serum IgA levels, reduction 
of phagocytosis, decrease of NK-cells) (Bergendiova et al., 2011; Nieman et al., 2002; Tiollier 
et al., 2005) and also possible prevention of these changes with some immunomodulators 
such as beta-glucans has been achieved (Bergendiova et al., 2011). It was also observed, that 
infants attending swimming pool during the first year of life have higher frequency of RRI 
and otitis media (Nystad et al., 2003).  
6.5 Positive family history on atopic diseases 
Positive family history on atopic and allergic respiratory diseases is significantly associated 
with increased risk of recurrent wheezing in children (Chong & Neto, 2010). On the other 
hand, the recurrent respiratory infections do not protect these children from the development 
of the atopic diseases of the airways (Balemans et al., 2006; Ciprandi et al., 2006). The children 
of parents with atopy have higher risk of respiratory tract infections (Nystad et al., 2003). 
6.6 Atopy 
Non-recognised allergy could lead to the similar clinical picture as RRI or could make the 
airways more susceptible to the infectious agents, esp. viruses. The relation between atopy 
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and RRI has been evaluated in several studies, but the results were inconclusive. It was 
documented, that atopy is a frequent condition among the children with RRI and it is likely 
that atopy is a favouring factor for RRI (Dellepiante et al., 2009). Atopy affects 15-20% of 
children and causes chronic inflammation of the airways that can mimic recurrent of chronic 
upper respiratory infections. Atopy can also facilitate the adherence of pathogens to the 
respiratory epithelium and thus promote infections (Ballow, 2008). Allergic children have 
more numerous and severe respiratory infections than non-allergic children (Ciprandi et al., 
2006).  
7. Diagnostic approach to the child with recurrent respiratory infections 
The assessment of the children with RRI is demanding: it requires close attention to the 
history and examination, and in the selected cases, extensive investigations. Early and 
accurate diagnosis is essential to ensure that optimal treatment is given and to minimize the 
risk of progressive or irreversible lung damage. The challenge for the physicians is to 
distinguish between the child with self-limiting or minor problems and the child with 
serious, perhaps progressive lung disease. The most common and frequent symptoms of 
recurrent respiratory infections is chronic cough. 
Diagnostic algorithm should be aimed on the exclusion of the underlying severe illness. The 
diagnosis of RRI is very probable if: 
 milder respiratory infection with the similar characteristics as the respiratory infections 
in children with normal respiratory “morbidity” (severity, duration, absence of 
complications, good response to the conventional symptomatic therapy and empirical 
antibiotic therapy), 
 the absence of severe and invasive systemic infections, 
 absence of failure to thrive, 
 negative family history for immune disorders. 
To the diagnostic algorithm of RRI belongs the investigation of the possible causes of 
chronic cough, such as allergy, asthma, ǂ1-antitrypsin deficiency, primary or secondary 
ciliary dyskinesias, congenital anomalies, gastroesophageal reflux (GER), recurrent 
pulmonary aspiration of post-nasal drip syndrome (the most frequent cause of chronic 
cough in children) (de Martino & Ballotti, 2007). The recurrence of the infections in the same 
specific site should be aimed the attention to the possible congenital developmental 
anomalies of the respiratory tract or the presence of foreign aspirated body. Recurrent or 
chronic infections can be associated with anatomic defects that characteristically involve one 
organ system (Panigada et al., 2009). Foreign body should be considered when the infections 
are chronic and localized to one anatomical sire, e.g. one ear canal or one nostril. Recurrent 
symptoms in small children accompanied by malabsorption or nasal polyps should be re-
evaluated for possible cystic fibrosis (CF), also despite negative neonatal screening. The 
incidence of CF is in some countries more common when compared with an incidence of 
PID. Therefore, the combination of above mentioned symptoms is indication to perform 
sweat test with the following genetic analysis. RRI can be also the sign of repeated 
aspiration of gastric content in GER, swallow dysfunction, under-diagnosed bronchial 
asthma or immotile cilia syndrome (Vaughan & Katkin, 2002). Recurrent otitis media is 
associated with Eustachian tube dysfunction secondary to atopy (Ghezzi et al., 2011).  GER 
is usually associated with asthma symptoms, but sometimes can be confused with bronchitis 
or lead to aspiration and recurrent pneumonias. GER can be also factor involved in the 
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pathogenesis of recurrent otitis media and sinusitis. Children who develop recurrent 
pneumonia from aspiration in association with GER tend to be younger than 2 years of age. 
Children who have a history of nocturnal cough or wheeze with exercise or protracted 
coughing after upper respiratory illnesses should undergo spirometry and assessment of 
bronchodilator responsiveness (Panitch et al., 2005). Recurrent sino-pulmonary infections 
with situs viscerum inversus may indicate immotile cilia syndrome (primary ciliary 
dyskinesia, Kartagener syndrome) (Ballow, 2008; Skeik & Jabr, 2011).  
The evaluation of the frequency of respiratory infections is usually less important, that the 
assessment of other characteristics of RRI such as: 
 the course of the infections, 
 alteration of the general health status, 
 duration, 
 accompanying fever, 
 possible complications, 
 response to the standard symptomatic therapy, 
 response to the empiric antibiotic treatment, 
 causal isolated pathogen. 
The diagnostic algorithm for children with RRI contains (de Vries, 2001; Slatter & Gennery, 
2008): 
 ENT examination with exclusion of adenoidal hypertrophy, 
 chest X-ray, 
 determination of specific IgE or the performance of skin prick test with common 
inhalant and food allergens, 
 measurement of total IgE levels in serum, 
 determination of the levels of IgG, IgA and IgM in serum, 
 blood cell count together with absolute count of lymphocytes, neutrophil and 
eosinophil granulocytes, 
 bacteriological cultivation and serological tests, 
 viral serological tests, 
 in selected patients:  
 levels of IgG-subclasses, 
 production of specific post-vaccination antibodies against Streptococcus pneumoniae, 
Haemophilus influenzae type b, tetanus and diphtheria toxoids taken 4 weeks after 
vaccination of not previously exposed to vaccine antigens, 
 levels of C3 and C4 components of complement, mannose-binding lectin and 
functional tests of complement system (CH50, AP50). 
8. Treatment and prevention of recurrent respiratory infections 
The children with RRI represent a great challenge for the paediatricians, from both 
therapeutic and preventive standpoints. It is necessary to determine whether these RRI are 
because of host-derived factors or are the result of increased environmental exposure. Host 
derived factors may be non-immunological and immunological (related to host 
immunodeficiency.  
In recent years, following the increase in the incidence of antibiotic resistance, interest in 
preventive treatment has intensified. Such treatment should contribute to the prevention of 
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RRI, thus reducing the usage and excessive consumption of antibiotics (Marseglia et al., 
2007). A diagnosis of viral infection does not justify prescription of antibiotics.  
Recent approach in the prevention of RRI includes the encouragement of breastfeeding, the 
use of intravenous or subcutaneous immunoglobulins and respiratory syncytial virus 
immune globulin, as well as methods of stimulating immunity, such as bacterial lysates or 
various nature-based products (Bellanti, 1997). 
8.1 Bacterial extracts (lysates) 
Since the 1970s, when using of bacteria-derived immune modulators started, several 
products were developed and their using becomes very popular around the world. 
Currently more than 8 million patients are treated with bacterial extracts every year and 
approximately 150 million patients have been treated since their licensing (Bousquet  
Fiocchi, 2006).  
Bacterial extracts are made from different bacterial species most frequent responsible for 
recurrent respiratory or urinary tract infections. The most often included species are: 
Staphylococcus aureus, Streptococcus viridans, Streptococcus pneumoniae, Streptococcus pyogenes, 
Klebsiella pneumoniae, Klebsiella ozenae, Moraxella catarrhalis, Hemophilus influenzae. Bacterial 
extracts are usually administered orally, although subcutaneous or intranasal forms were 
tested sooner (Braido et al., 2007 Matricardi et al., 2003).  
Bacterial immune modulators could be divided into two-generation preparations:  
1. First generation products are bacterial extracts containing killed bacteria or their lysate.  
2. Second generation products contain the most immunogenic components of bacteria 
(e.g. ribosomes, proteoglycans).   
Bacterial extracts stimulate both non-specific and specific immunity mechanisms through 
naturally evoked immune response. The intrusion of pathogen in the human body leads first 
to non-specific response and consequently to specific response for the epitopes of the 
pathogen. Bacteria recognition and response takes place in mucosal associated lymphoid 
tissue (MALT). Typically bacterial extracts are administered orally and absorbed in the 
intestine, triggering Payer’s patches in gut associated lymphoid tissue (GALT). M-cells in 
Payer’s patches are responsible to bacterial recognition. Toll-like receptors (TLR) and other 
receptors recognize components common to a range of bacteria (e.g. lipopolysaccharide, 
peptidoglycan, lipoteichoic acid, lipoarabinomannan, un-methylated DNA with CpG motif 
and bacterial lipoproteins), so-called pathogen-associated molecular patterns (PAMPs). 
Interactions between PAMPs and TLR result in the activation of dendritic cells, 
macrophages, NK cells with cytokines and chemokines production, activation of 
phagocytosis and early pathogens destruction. Enhanced innate immune response also 
stimulates adaptive immune response. Antigen-specific T and B cells are generated in the 
Payer’s patches as well as a considerable number of lymphoblasts, mostly IgA+ precursors 
of the IgA producing plasmocytes. Lymphocytes and lymphoblasts maturate in mesenteric 
lymph node and subsequently migrate into mucosal associated lymphoid tissue in different 
organs. The protective effect of bacteria-derived immune modulators is particularly related 
to memory cells and antigen-defined induction of immunoglobulin synthesis, mostly IgA, 
with quick and specific immune response after future contact with the same antigen (Braido 
et al., 2007 Del-Rio-Navarro et al., 2006 Rozy  Chorostowska-Wynimko, 2008).  
In vitro studies showed that the action of OM-85 BV is mediated, at least in part, by the 
activation of TLR2 and TLR4 (Alyanakian et al., 2006). Proteoglycans from cell membrane of 
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Klebsiella pneumoniae strain has been described as a potential TLR-2 inducer (Bellanti et al., 
2003). Bacterial extracts enhance natural killer cells activity, increase production of 
proinflamatory cytokines, increase the expression of adhesion molecules in phagocytes, 
inhibit serum induced IL-12 expression in peripheral blood lymphocytes (Rozy  
Chorostowska-Wynimko, 2008 Matricardi et al., 2003). Bacterial extracts up-regulated 
oxidative metabolism, superoxide anion and nitric oxide production (Manuel et al., 1989). 
Bacterial immune modulators induce maturation of dendritic cells enhanced expression of 
CD83, CD86 and HLA II molecules - markers of dendritic cells maturation has been 
observed following bacterial extracts application. Dendritic cells might be important for 
preferential triggering of TH1 response (Boccaccio et al, 2002 Zelle-Rieser et al., 2001). In 
newborn animals bacterial extracts increase IFN- and decrease IL-4 productions, which 
contribute to preferential development of the TH1 immunity (Bowman  Holt, 2001). 
Various clinical trials with children, both young (< 6 yrs) as well as school children, have 
demonstrated positive effect of bacterial extracts mostly on frequency, duration of the 
infection episodes and less antibiotic requirements. Recently, reduction of rate and duration 
of wheezing attacks and improvement of atopic dermatitis after treatment with bacterial 
extracts in children has been described (Brunetti et al., 2005 Razi et al., 2010). On the other 
hand, some studies have not demonstrated preventive effect of bacterial immunotherapy 
(Saracho-Weber et al., 2001 Vautel et al., 1993).  
Findings from different clinical trials have been evaluated and summarized with some 
review and meta-analysis. However, due to heterogeneity and often the poor quality of the 
trials, the results should be interpreted with caution. Cochrane meta-analysis from 2008 
evaluated the effect of all used immune modulators to acute respiratory tract infections in 
children. 34 placebo-controlled trials were included (24 with bacterial extracts). This review 
showed that immunostimulants reduce the incidence of acute respiratory infections in 
children, by 40% on average. The subgroup analysis of bacterial extracts studies produced 
similar results, with lower heterogeneity (Del-Rio-Navarro et al., 2006). In review performed 
by Braido et al. (2007) both in children and adults protective effect of bacterial extracts was 
found such as general reduction of infection rates, reduction of their duration, beneficial 
effect on symptoms, and reduction of the use of antibiotics. Bousquet & Fiocchi (2006) 
review demonstrated that ribosomal immunotherapy reduces number, duration, and 
severity of infectious episodes, reduce antibacterial use and the likelihood of consequent 
development of bacterial resistance. Other favorable results included a reduction in 
antibacterial treatments, shorter duration of recurrent episodes, reduced need for other 
medications, smaller number of lost school days or parent absenteeism from work, less 
fever, and reduced hearing loss (Bousquet  Fiocchi, 2006). In other review the effect of OM-
85 BV to acute respiratory infections in children were examined. 13 included trials were of 
low or moderate quality. There was a trend for fewer and shorter infections and a reduction 
of antibiotic use in group treated by bacterial extract versus placebo, but with weak 
evidence (Steuer- Stey et al., 2007). Recently, other meta-analysis with OM-85 BV has been 
published. This meta-analysis includes 8 randomized controlled trials and shows significant 
decrease of recurrent respiratory tract infections frequency. The effect seems to be greater in 
patients at increased risk of RRI (Schaad, 2010).  
Safety and tolerance of bacterial extracts in all paediatric trials were good. Adverse events 
occurred occasionally and were mild and transitory with rapid resolution. The majority of 
adverse events were gastrointestinal or cutaneous findings. Reported adverse effects 
included eczema, urticaria, diarrhoea, abdominal pain, headache, rhinitis, and cough. No 
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serious adverse events in relation with bacterial extracts treatment have been reported in the 
literature (Del-Rio-Navarro et al., 2006 Olivieri et al., 2009 Schaad, 2010). No casual 
association between bacterial extracts and autoimmunity disease has been reported in 
literature (Olivieri et al., 2009).     
8.2 Biologically active polysaccharides (glucans) 
Metabolites and components of fungi have been used in medicine for many centuries in 
order to exploit the properties of several of their active compounds. Many of these 
substances naturally contained in fungi have demonstrable effects on different components 
of the immune system. The most important groups of these immunomodulating substances 
include: polysaccharides (glucans in particular), polysaccharide peptides, polysaccharide 
proteins and proteins. The main mechanism is their mitogenic and activating effect on 
different populations of immunocompetent cells, such as hemopoietic stem cells, 
lymphocytes, macrophages, dendritic cells and NK cells, and subsequent production of 
several cytokines with complex effects. Besides typical immune system cells, glucans also 
have demonstrable effects on other cell populations, such as fibroblasts, keratinocytes, or 
other connective tissue cells. This is why many clinical and experimental studies have 
focused on the effects of these substances on the prevention and treatment of acute and 
recurring infectious diseases, congenital and acquired immune disorders, oncologic, 
autoimmune and allergic diseases (Lull et al., 2005; Vetvicka & Vetvickova, 2009). 
Glucans are polysaccharides of natural origin, naturally appearing in fungi, plants and some 
bacteria. In fungi, they represent the main component of cell walls, and are composed of 
glucose molecules bound with two types of bonds: ǃ-(1ń3) in the main linear chain and ǃ-
(1ń6), which binds side chains of variable length to the main polysaccharide chain. 
Immunomodulating effects of various extracts from fungi have been known for a long time, 
but recently, the attention has been focused mainly on glucans, which occur in nature as a 
typical structural element of fungal cell walls. They represent a large group of natural 
substances with immunomodulating effects, and the structure and mechanism of action of 
many of them have been described in detail. Particular glucans differ in the intensity of their 
immunostimulating/immunomodulating effect. Imunoglucan – pleuran (Pleurotus ostreatus, 
Oyster mushroom), Schizophyllan (Schizophyllum commune, Split gill) and Lentinan (Lentinus 
edodes, Shiitake mushroom) are considered the most effective ones (Lull et al., 2005). 
There are several possible mechanisms of action of glucans on the immune system. The 
activation of human immune system is enhanced through a system of receptors that are able 
to recognize the so called molecular patterns of microorganism pathogenicity (PAMPs, 
pathogen-associated molecular patterns). Receptors able to identify these PAMPs include mostly 
those that are involved in recognizing extracellular pathogens – Toll-like receptors and C-
type lectin receptors. On the other hand, the activation of these receptors triggers a cascade 
of inflammatory response associated with subsequent release of many cytokines, 
chemokines and other soluble factors that lead to the activation of several populations of 
immunocompetent cells of both specific and non-specific part of the immune system, and 
the development of antigen-specific immunity (Vetvicka & Vetvickova, 2009). The ability of 
glucans to activate various components of the immune system and thus modulate the 
immune response depends on the length of their chain, level of branching, as well as on 
their tertiary structure (Bohn & Bemiller, 1995). The ability of glucans to modulate the 
immune response has many potential applications in both clinical and experimental 
medicine in order to provide an effective defence against negative influences from both 
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external (e.g. microorganisms) and internal environment (e.g. tumour or damaged cells). 
Many studies focused on the effects of parenterally administered glucans, although the 
research has confirmed that they are also active and effective when administered orally 
(Hong et al., 2004). Among all the glucan receptors (dectin-1, Toll-like receptors, 
complement receptor 3, so called scavenger receptors, lactosylceramide, etc.), the most 
important is dectin-1, which is a primary receptor for glucans at least on the surface of 
leukocytes and plays an essential role in immunomodulation mediated through glucans 
(Brown & Gordon, 2003; Chen & Seviour, 2007). Whether particular glucans show 
immunostimulating or immunosuppressive effects in different phases of the immune 
response depends on the dosage, method of application, frequency of administration, as 
well as on the overall state of the organism' immune system. 
Glucans act on the immune system on many levels. Among all the known mechanisms, the 
following should be highlighted in particular (Chen & Seviour, 2007; Kodama et al., 2002; 
Lehne et al., 2006; Lesourd, 1997; Wasser, 2002): 
 Ń metabolic and functional activity of immunocompetent cells (specific and non-specific 
immunity), 
 Ń proliferation and differentiation of both T and B lymphocytes, 
 Ń content of secretory IgA antibodies in saliva, thus increasing local defence of mucous 
membranes, 
 Ń phagocytosis ń Ń effectiveness of immune response to both endogenous and 
exogenous stimulus, 
 Ń bactericidal activity of monocytes and neutrophils, 
 they activate complement cascade through both classic and alternative pathways with 
subsequent formation of many compounds with direct or indirect immunomodulating 
effect, 
 stimulating effect on NK cells ń Ń defence against intracellular viral, bacterial and 
parasitic infections, 
 Ń phenotypic and functional maturation of dendritic cells (DC), they potentiate the 
stimulating effect of DC on the proliferation of T lymphocytes and increase the 
expression of several differentiating marks on the surface of DC (e.g. MHC I, MHC II, 
CD-86, CD-80, etc.) ń more effective presentation of foreign antigens, 
 Ń release and activity of many enzymes (such as lysozyme, elastase, collagenase, nitric 
oxide synthase), complement components, cytokines (IL-1ǃ, IL-10, IL-12, IL-18, TNF-ǂ, 
IFN-Ǆ, GM-CSF), other signal molecules (nitric oxide and other nitro-compounds) ń 
proliferation of immunocompetent cells, their migration, Ń bactericidal and cytocidal 
effect, 
 they have a regulatory effect on the differentiation of TH1/TH2 lymphocytes ń Ń Th1 
immune response ń Ń IL-10, IL-2, IL-18 ń reduction of the symptoms of allergic 
diseases and prevention of the development of atopy, 
 Ń TH1 cytokine response with simultaneous suppression of Th2 response ń potential 
use in diseases and states associated with Th1 response insufficiency (e.g. type II 
diabetes mellitus, ageing), as well as in diseases with inadequate stimulation of TH2 
response (e.g. allergic diseases).  
One of the most important indications of glucans application in children are recurring 
infections of upper and lower respiratory tract, primary and secondary immunodeficiencies 
of different etiology, as well as repeated administration of antibiotics. Semberova et al. 
(2009) observed a significant decrease in the volume of adenoid vegetation in children after 
40-days treatment using a product containing glucan.  
www.intechopen.com
Recurrent Respiratory Infections in  
Children – Definition, Diagnostic Approach, Treatment and Prevention 
 
131 
The effect of imunoglucan (Imunoglukan P4H® syrup) on the course and frequency of 
recurrent infections of upper respiratory tract has shown also multi-centric study. A positive 
response to the treatment, i.e. ≥50% reduction of the frequency of recurrent respiratory 
infections, was observed in 153 children (71.2%). The average annual incidence of 
respiratory infections in children with a positive response to the syrup was 3.6 and was 
significantly lower compared to that in unresponsive patients (3.6 vs. 8.9, p<0.001). The 
therapy did not show statistically significant effect on the frequency of febrile episodes, need 
for antibiotics or duration of infection. No adverse effects of Imunoglukan P4H® were 
reported, with the therapy being very well tolerated. This study proved the therapeutic and 
preventive effects of biologically active polysaccharides on the frequency of recurrent 
respiratory infections in children (Jesenak et al., 2010). 
8.3 Systemic enzyme therapy 
A therapeutic method consisting of a systemic peroral administration of special combined 
mixtures of enzymes has been gradually developed since the middle of the 20th century. 
This method was named systemic enzyme therapy (SET). Initially, SET was applied only 
empirically. Currently, there are a number of relevant data about a biological availability of 
active substances, their complex activities as well about their favourable clinical effects in 
many inflammatory diseases (Honzikova et al., 2004). Originally, an empirical treatment of 
mainly inflammatory diseases due to the many controlled clinical studies was changed to a 
method which optimizes and modulates several immune functions disrupted in many 
pathological states. SET is predestinate to using in many indications by their targeted 
intervention into regulatory and biochemical pathways. The basic pharmacological effects of 
SET include anti-oedematous, fibrinolytic, anti-inflammatory and immunomodulatory 
activities (Biziulevicius, 1998; Kleine, 1998). Enzymes bind to the blood antiproteases after 
resorption through the mucosa of gastrointestinal tract and then they are distributed to sites 
of inflammation where they modulate and restore the imbalance in immune responses. They 
are involved in the activation as non-specific as specific immunity mechanisms 
(Biziulevicius, 1998; Desser et al., 2001; Douwe, 2005; Manhart et al., 2002; Targoni et al., 
1999; Zavadova et al., 1995; Zavadova & Desser, 1997). Enzyme therapy can change the 
expression of adhesion molecules and receptors on the surface of T lymphocytes, reduce the 
activation of many populations of immunocompetent cells and they increase the activation 
threshold of autoaggressive T-lymphocytes in the mechanism of specific immunity 
(Biziulevicius, 1998; Desser et al., 2001; Douwe, 2005; Lauer et al., 2001; Manhart et al., 2002; 
Targoni et al., 1999; Zavadova et al., 1995; Zavadova & Desser, 1997). Generally, we can say 
that SET is involved in the regulation of both acute and chronic inflammatory processes, as 
well as in the activation of individual components of the immune system. 
Many respiratory disease of infectious or allergic etiology became an important indication 
for the using of SET. SET has only additional importance in the case of allergic diseases and 
it normalizes disrupted functions of immune system. SET appears to be a good adjuvant 
treatment of atopic dermatitis and asthma. SET reduces the number of febrile states, helps to 
reach a compensation of disease and reduces the dose of inhaled corticosteroids in asthmatic 
patients. Many studies have demonstrated the effect of SET in recurrent respiratory 
infections. The Czech post-multicenter study compared the effect of SET (preparation 
Wobenzym ®) and the bacterial immunomodulators (BIM) on the course and recurrence of 
respiratory infections in a cohort of 468 children aged 3-18 years. In both groups, there was a 
statistically significant decrease in the average number of respiratory tract inflammation  
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(by 59% in SET and 32% for BIM) and the average number of related antibiotic treatments 
(68% in SET and 35% for BIM). The positive results achieved by the administration of SET 
can be explained by favourable immunomodulatory effects of these preparations 
(Honzikova et al., 2004). Similar effects were also observed other authors (Helms and Miller, 
2006; Lanchava et al., 2005; Zavadova et al., 1995). Interesting finding was also the observed 
improvement in spirometric lung function indices following the application of SET in 
children with recurrent obstructive bronchitis (Lanchava et al., 2005). SET administration is 
also effective in the treatment of acute or chronic sinusitis, tonsillitis, acute and recurrent 
laryngitis and chronic secretory otitis media (Vegh & Vegh, 2009). In patients with elevated 
IgE, the application of SET can result in the decline or even normalization of their levels. 
8.4 Isoprinosine 
Isoprinosine (inosiplex, inosine pranobex) is a synthetic immunomodulating agent with 
pluripotent effects on the immune system. It possesses T-lymphocyte and phagocyte 
function enhancing immuno-modulating effect similar to those of another synthetic drug, 
levamisole. Isoprinosine was developed as an anti-viral agent, but in reality, the action of 
Isoprinosine in viral infections has been attributed to immunomodulatory rather than direct 
anti-viral effects. In vitro, Isoprinosine enhances T-lymphocyte function, stimulates NK cell 
activity, macrophages and neutrophils. It increases IL-1, IL-2 and interferon gamma 
production and up-regulates interleukin-2 receptor expression. The data on the effect of this 
agent on the frequency a re-occurrence of RRI are conflicting. The study of Litzman et al. 
(1999) does not support the continued use of Isoprinosine in the prevention of RRI in 
children with normal immune systems. The use of Isoprinosine in the patients with mild but 
clearly defined immunodeficiencies is probably effective (Litzman et al., 1999).  
8.5 Transfer factors 
Transfer factors (TFs) present a complex of low-molecular biologically active substances 
with possible effect of normalization of the disturbances in humoral and cellular immunity. 
Transfer factors are small proteins that "transfer" the ability to express cell-mediated 
immunity from immune donors to non-immune recipients. We developed a process for 
purifying specific transfer factors to apparent homogeneity. This allowed us to separate 
individual transfer factors from mixtures containing several transfer factors and to 
demonstrate the antigen-specificity of transfer factors (Kirkpatrick, 2000). The treatment 
with TFs is an active immunotherapy, which is based on the application of the substance 
with the capacity to influence the reactivity of the organism to different immunogenic 
impulses. TFs act as an antigen-dependent, antigen-specific micromolecular polypeptide 
cytokine. There are two possible sources of TFs: the extract from the peripheral bovine or 
human leucocytes. The mechanism of TFs action consists from the influence of both specific 
and non-specific immunity (Barnet et al., 1996; Bystron et al., 1996).   
Several studies have demonstrated the effect of TFs in the treatment and prevention of 
recurrent respiratory or urinary infections in children and also in adults (Anttila et al., 1977; 
Grohn, 1977; Jose & Ford, 1976). TFs can be used also in the prevention of recurrent herpetic 
infections, in different secondary immunodeficiencies (especially of cellular immunity) or as 
a complementary therapy of psoriasis vulgaris, atopic eczema, sepsis or chronic fatigue 
syndrome. It is also possible to apply Tfs in the cases without confirmed immunodeficiency 
(Jones et al., 1981; Meduri et al., 1996; Pizza et al., 1996).  
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8.6 Thymus hormones 
On the market there are available preparations containing extract of thymus from different 
animals. These products are generally recommended as a dietary supplement to restore and 
strengthen the immune system. They are polypeptide complexes: peptides and signalling 
factors designed to optimize intercellular communication between cells of the immune 
system and for maturation, proliferation and activation of T-lymphocytes. Extracts of 
thymus contain complex mixture of peptides with a stimulating effect on T-lymphocytes 
and they are called thymus hormones. They have immuno-normalizing effect, so do not 
affect normal immune function, but reduced functions return to the normal state. Among 
the indications of using of these products are included acute, chronic and recurrent 
respiratory infections. They are non-toxic, with minimum side effects. This preparations are 
contraindicated for pregnant and breastfeeding women and patients taking 
immunosuppressants. Nowadays their production is stopped and it is tested the production 
of synthetic analogs (Ambrogi et al., 1983; de Mattia et al., 1993; Longo et al., 1988). 
8.7 Vitamins and minerals 
Vitamins and minerals are necessary for normal immune system function. Low levels of 
vitamins and minerals, caused mainly by malnutrition, lead - besides other complications - 
to increase of infection rate. It is questionable if prophylactic treatments in “healthy” 
subjects can influence frequency and duration of respiratory tract infections.   
Numerous studies have evaluated effect of vitamin C supplementation to prevention of 
respiratory tract infections with various results. Preventive treatment with vitamin C 
reduced cold duration and severity of symptoms (Douglas et al., 2004).   
Several trials and meta-analysis have examined prophylactic use of zinc for respiratory tract 
infections with mixed results (Aggarwal et al., 2007 Mathew, 2010). In some children 
studies decrease incidence of upper or lower respiratory infections has been observed 
(McElroy  Miller, 2002 Roth et al., 2008).  
Also clinical trials examining effect of routine vitamin A supplementation to prevention and 
treatment of respiratory infections have yielded contradictory results; no significant effect in 
children has been observed (Roth et al., 2008).  
8.8 Prebiotics, probiotics & nucleotides 
Breastfeeding is associated with a significant decrease incidence of respiratory infections. 
Breast milk contains variety of substance with antimicrobial, anti-inflammatory and 
immunomodulatory activity. High concentration of oligosaccharides in breast milk induces 
accurate colonization of infant neonatal tract, predominantly with Bifidobacteria and 
Lactobacili. Healthy gut flora protect against infection via a number of mechanisms including 
competitive inhibition of epithelial binding by enteropathogenic bacteria and effects on tight 
junctions. Accurate colonization plays also important role in the development of mucosal 
and systemic immune system, and tolerance to non-pathogenic antigens (Jones et al., 2010).  
Nonhuman milk oligosaccharides - prebiotics, such as small-chain galacto-oligosaccharides 
and long-chain fructo-oligosaccharides are used to substitute these functions in formula-fed 
infants. Supplementation with neutral oligosaccharides leads to optimalized colonization 
like in breast-feeding infants, but the clinical outcomes are not conclusive yet. Reduced 
incidence of atopic diseases has been described (Arslanoglu et al., 2008 Moro et al. 2006). 
Some studies confirmed positive effect of oligosaccharides supplementations in infant 
formula to incidence of respiratory infections (Arslanoglu et al., 2007).  
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Breast milk is also rich in nucleotides with immunomodulatory activity. Beneficial effect of 
nucleotides supplementations in formula-fed infants on various components of the immune 
system has been reported. Nucleotides added to infant formula augment infantile NK-cell 
activity and humoral response and my have limited protection against diarrhoea (Jones et 
al. 2007, Pickering et. al, 1998).  
Probiotics are defined as “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host” (FAO/WHO). The most common bacteria in 
this group include Bifidobacteria and Lactobacili. Use of probiotics early in life could favour 
correct maturation of the immune system, and reduce development of allergy. Effects of 
probiotics include competitive inhibition with pathogenic bacteria, immunomodulation of 
local immunity (maintains gut wall integrity) and systemic immunity (enhances non-specific 
and specific response) (Singh  Das, 2010). The most documented efficacy of probiotics is in 
the treatment and prevention of infectious and antibiotic-associated diarrhoea. Probiotics 
are generally regarded as safe, but caution must be given in immunocompromised patients. 
Only a limited number of trials have evaluated the potential effect of probiotics in reducing 
the risk respiratory tract infections with inconsistent results. Studies differed in the probiotic 
strains evaluated, indications for use, dosing or study design. Review of 14 performed trials 
showed, that probiotics may have a beneficial effect on the severity and duration of 
symptoms, but do not appear to reduce the incidence of RRI (Vouloumanou et al., 2009).  
8.9 Echinacea extracts 
Non-prescriptional natural therapeutics are used widely and their popularity continue to 
increase, including children’s treatment. Usually these products are well tolerated and 
believed to be safe, but the true safety is often unknown. Usually there are limited data 
about efficacy, mechanism of action, active components, and potential drugs – herbal 
interactions. Well-controlled trials with reliable data about different products are often 
missing.    
Echinacea extracts are one of the most frequent used herbal preparations, especially in North 
America. Traditionally these herbs were used by indigenous peoples for the treatment of 
many illnesses (colds and other respiratory diseases, wound healing, candidiasis). 
Nowadays Echinacea extracts are predominantly used for treating and preventing 
respiratory tract infections, mainly common cold and influenza. 
The photochemical composition of Echinacea preparations may differ widely both between 
and within species. Echinacea products contain variable amounts of ingredients with 
pharmacological activity, such as polysaccharides, flavorous, chicory acid glycosides, 
essential oils, oxyacetylene and alkyl amides (Gunning, 1999). The biological activities of 
Echinacea appear to be the result of a combined action of its components rather that of one 
single group.  
Several studies have shown in vitro and in vivo effects on immunological parameters, but 
until now the clear immunomodulatory mechanism has not been identified. Echinacea 
appears to affect mainly non-specific immune response. Macrophage activation, enhanced 
neutrophil phagocytosis and cytokine expression has been reported (Melchart et al., 1995 
Synching et al., 2006). Stimulation of the cannabin receptor (CB2) by alamedas present in 
Echinacea could also play a role in immunomodulatory activity (Rudner et al., 2006). 
Bactericidal effect against some of the bacteria (Streptococcus pyogenes, Homophiles influenzae, 
Legion Ella pneumophilla) and direct antiviral effects have been also described (Fusco et al., 
2010 Sharma et al., 2010). 
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Many clinical trials with different Echinacea preparations have been conducted with variable 
results on reduction, duration and severity of symptoms associated with respiratory 
infection. Majority of studies have been performed in adults for assessment the effect of 
Echinacea extracts in the treatment of acute infection, mainly common cold. Some studies 
have reported decrease frequency, duration and severity of respiratory tract infection, but 
some did not find any positive effect of Echinacea treatment (Barrett et al., 2010 Goel et al., 
2004 Melchart et al., 1998 O´Neil et al., 2008 Sperber et al., 2004). In children’s study was 
found no effect on duration of illness or severity of symptoms. Treatment with Echinacea 
was associated with increased risk of rash compared with placebo group (Taylor et al., 
2003). In other study treatment with extract of Echinacea, vitamin C and propolis reduced 
significantly number and duration of illness episodes in children when compared with 
placebo treated group (Cohen et al., 2004). Several meta-analysis were performed with great 
heterogeneity of trials and results suggest that Echinacea extracts might have beneficial effect 
in the early treatment of common colds, but the there was insufficient evidence to suggest 
an effect on prevention (Gilles et al., 2000 Linde et al., 2006 Shah et al., 2007). On the other 
hand, in other meta-analysis Echinacea extracts were effective in prevention of the common 
cold after clinical inoculation (Schoop et al., 2006).    
Echinacea products apart from allergic reactions and increased incidence of rash are reported 
to be generally safe (Mullins, 1998 Mullins  Heddle, 2002). Echinacea preparation should 
not be used by patients with allergy to other members of the Asteraceae family due to 
possible cross-reactivity. Echinacea extracts should be avoided by patients with progressive 
immune diseases, on treatment with corticosteroids and immunosuppressants. Echinacea 
should not be taken orally for more than 8 weeks because of the potential for decreased 
immune response after a long-term application (Gunning, 1999).  
8.10 Ginseng  
Ginseng is composed of a number of different species, which belong to the same plant 
family, the Araliaceae. Korean, Japanese and American ginseng belong to the genus Panax, 
whereas Siberian ginseng is of the genus Eleutherococcus (Vohra et al., 2008). 
Polysaccharide and oligosaccharide fractions are responsible for the immunomodulating 
effects of North American ginseng (Panax quinquefolium L., Fam. Araliaceae), glykosides 
called eleutherosides for effects of Siberian ginseng (Mc Elhaney et al., 2004 Roxas et al., 
2007). 
Ginseng products in vitro induce the production of INF-, TNF-, IL-1, IL-2, IL-6, stimulate 
natural killer cell activity, increase phagocytosis. B-cell proliferation in the spleen with 
increased circulating immunoglobulin G levels has also been demonstrated (Jie et al., 1984 
Kim et al., 1990 Wang et al., 2001). Subjects who took extract of Siberian ginseng for one 
months have had a significant increase in total lymphocyte, T helper, T suppressor, natural 
killer and B lymphocyte cells counts compared to placebo. In vitro liquid extract of the 
Siberian ginseng root inhibits replication of RNA viruses (Glatthaar-Saalmuller et al., 2001). 
Extracts appear to have cytotoxic effects on a wide range of tumour cell lines.   
Clinical studies performed mainly in adults showed variable results (Mc Elhaney et al., 2004 
Preddy et al., 2005). In the reviews of 5 trials with North American ginseng there was 
insufficient evidence to conclude that ginseng reduces the incidence or severity of common 
colds. It appears to be effective in shortening the duration of cold or acute respiratory 
infections (Seida et al., 2009). In one trial with Siberian Ginseng decrease frequency of 
respiratory infections in children was observed (Vohra et al., 2008).  
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8.11 Astralagus 
Astralagus membranaceus is rich in polysaccharides, flavonoids, multiple trace minerals and 
amino acids, all of them contribute to Astragalus’s complex immunomodulatory properties. 
Astralagus demonstrated activation and proliferation of immune cells, particularly CD8+ 
and CD4+ T lymphocytes compared to placebo. In one trial with small number of children 
treatment with Astralagus extract reduced incidence of respiratory tract infections (Roxas  
Jurenka, 2007).  
8.12 Viscum album   
Viscum album extracts were shown to have immunomodulatory functions, especially on NK 
cell functions (Braedel-Ruoff, 2010). Viscum album is widely used in complementary 
medicine for the treatment of cancer. The effects on frequency of recurrent respiratory 
infections were examined in one trial in children living in areas exposed to the radioactive 
fallout from Chernobyl. Preparations were effective in reducing frequency of infections and 
reducing clinical symptoms (Chernyshov et al., 2000).  
8.13 Propolis 
Propolis, the bee’s product, has highly variable composition, depending on geographic 
location, plant species and the season of collection. Biological activity is mainly due to 
flavonoids, terpens, caffeic, ferulis and cumaric acids and esters. Anti-microbial and anti-
inflammatory properties of propolis documented in some in vitro studies may be useful for 
prevention of upper respiratory tract infections (de Vecchi  Drago, 2007).  In children with 
recurrent acute otitis media suspension of propolis and zinc significantly reduce the risk of 
new acute otitis media episodes (Marchisio et al., 2010). Because of pollen containing in 
propolis suspension there is a risk of allergic reactions and sensitisation and preventive 
treatment with propolis should not be recommended in general for children.  
8.14 Other natural products 
Different natural products declare to have immunomodulating properties or be assigned to 
treatment and prevention of acute respiratory disease (e.g. elderberry, garlic, larch 
arabinogalactans - polysaccharides from Larix occidentalis, olive leaf extracts, tea tree oil, 
colostrum). Until now insufficient number of trials with these preparations have been done, 
frequently only in vitro studies, or with small number of participants (rarely with children) 
and questionable quality, so it is difficult to make any conclusions regarding use of these 
preparations in prevention of acute respiratory tract infections.    
9. Follow-up and education 
When a diagnosis of RRI has been formulated, parents or care-givers should be reassured 
about the benign and transient nature of this condition. Accurate environmental prophylaxis 
and regimen changes are crucial. When RRI diagnosis has been formulated, removal of 
environmental risk factors (e.g. precocious day-care attendance, reducing the smoking in the 
household) must first be suggested. In some cases, the postponed enrolment of children at 
day-care centres could be the solution for the prevention and decrease number of RRI. 
Optimal day-care centres enrol only a limited number of children, have large clean rooms 
with a good ventilation to guarantee the removal of the air suspended microbial agents and 
are located in modern buildings in areas with less air pollution (de Martino & Ballotti, 2007; 
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Uhari et al., 1999). Prophylactic antibiotic treatment is neither indicated nor useful, even 
could interfere with normal development of the mucosal microflora and immune system 
functions. In the selected children, adenoidectomy and tonsillectomy should be 
recommended according to the validated guidelines (Frohna, 2005). Children with RRI are 
“immunologically normal” and therefore intensive impacts into the developing immune 
system can be harmful and contra-productive.  
10. Conclusion 
Respiratory diseases belong to the most frequent and common disorders in clinical praxis of 
every paediatrician. Recurrent viral infections are part of the growing up process of any 
child. Especially in children we can observe some which suffer from recurrent upper or 
lower respiratory tract infections. In general, a thriving child with recurrent respiratory 
infections does not suffer from a serious underlying disease. Most of the children do not 
have an immunodeficiency, but if they do, this often concerns an antibody deficiency. It 
there positive history for immunodeficiency, detailed immunological investigation is 
mandatory. In other children, immunological examination should be performed after the 
exclusion of other, more frequent causes of RRI such as gastroesophageal reflux, allergy or 
ENT focal infection (adenoidal hypertrophy). Treatment and prevention of these infections 
has its own rules and should consist of early, aimed antibiotic therapy acute attacks of 
infection, long and appropriate reconvalescence, elimination of all possible focuses and 
origins of infection and complete examination of the child’s immunostatus. There are 
several possibilities of immunomodulating therapy. Many clinical and experimental trials 
have confirmed their efficacy and pharmacological safety. The prescription and application 
of each immunomodulation agent should be performed in correct manner only in indicated 
cases with individual approach to each child taking into account all the rules of 
immunomodulation therapy. 
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